FAU.de
Deutsch
Login
Home
Publications
Research Grants
Inventions & Patents
Awards
Additional Research Activities
Faculties & Institutions
Research Areas
Professur für Translationale Frauenheilkunde und Geburtshilfe
Friedrich-Alexander-Universität Erlangen-Nürnberg
Medizinische Fakultät
Einrichtungen, die zum Universitätsklinikum Erlangen gehören
Department of Obstetrics and Gynaecology
Lehrstuhl für Geburtshilfe und Frauenheilkunde
Overview
Publications
(880)
Research Grants
(4)
Types of publications
Toggle all
Journal article
Journal article
Book chapter / Article in edited volumes
Book chapter / Article in edited volumes
Authored book
Authored book
Translation
Translation
Thesis
Thesis
Edited Volume
Edited Volume
Conference contribution
Conference contribution
Other publication type
Other publication type
Unpublished / Preprint
Unpublished / Preprint
Publication year
From
To
Abstract
Journal
Filters (inactive)
Polygenic Risk Scores for Prediction of Breast Cancer and Breast Cancer Subtypes (2019)
Mavaddat N, Michailidou K, Dennis J, Lush M, Fachal L, Lee A, Tyrer JP, et al.
Journal article
Impact of nab-paclitaxel dose reduction on survival of the randomized phase III GeparSepto trial comparing neoadjuvant chemotherapy of weekly nab-paclitaxel (nP) with solvent-based paclitaxel (P) followed by anthracycline/cyclophosphamide for patients with early breast cancer (BC) (2018)
Untch M, Jackisch C, Schneeweiss A, Schmatloch S, Aktas B, Denkert C, Schem C, et al.
Conference contribution
Evaluation of the MammaTyperVR as a molecular predictor for pathological complete response (pCR) after neoadjuvant chemotherapy (NACT) and outcome in patients with different breast cancer (BC) subtypes (2018)
Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al.
Conference contribution
Validation of the MammaTyper (R) pathological complete response (pCR)-score as a predictor for response after neoadjuvant chemotherapy (NACT) in patients with early breast cancer (BC) (2018)
Fasching P, Laible M, Weber KE, Wirtz RM, Denkert C, Schlombs K, Schmatloch S, et al.
Conference contribution
Germline mutation status and therapy response in patients with triple-negative breast cancer (TNBC): Results of the GeparOcto study (2018)
Pohl E, Schneeweiss A, Hauke J, Moebus V, Furlanetto J, Denkert C, Fasching P, et al.
Conference contribution
Real-world effectiveness of ribociclib 1 aromatase inhibitor, or endocrine monotherapy, or chemotherapy as first-line treatment in postmenopausal women with HR-positive, HER2-negative locally advanced or metastatic breast cancer: The RIBANNA study (2018)
Fasching P, Decker T, Guderian G, Heim J, Jackisch C, Lueck HJ, Lueftner D, et al.
Conference contribution
Patient-reported outcomes (PROs) in advanced breast cancer (ABC) treated with ribociclib plus fulvestrant: Results from MONALEESA-3 (2018)
Fasching P, Esteva FJ, Pivot X, Nusch A, Beck JT, Chan A, Pieris-Gunatilaka A, et al.
Conference contribution
A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients (2018)
Häberle L, Erber R, Gaß P, Hein A, Jud S, Langemann H, Rauh C, et al.
Conference contribution
Tumor-infiltrating CD8-positive T-lymphocytes in tubo-ovarian high-grade serous cancer are associated with multiple germline variants in 22q12.1 in a genome-wide association analysis (2018)
Natanzon Y, Kobel M, Winham SJ, Armasu SM, Mccauley BM, Vierkant RA, Cunningham JM, et al.
Conference contribution
Joint genome-wide association study of endometrial cancer and ovarian cancer identifies a novel genetic risk region at 14q23.3 (2018)
O'Mara TA, Glubb DM, Buchanan DD, Lambrechts D, Hall P, Tham E, Trovik J, et al.
Conference contribution
‹
1
...
44
45
46
47
48
...
80
›